In early March 2021, Verovaccines GmbH, a company funded under the umbrella of the GO‑Bio funding programme of the Federal Ministry of Education and Research (BMBF), demonstrated the proof of concept for its fourth vaccine programme. The study was carried out in cooperation with the University of Veterinary Medicine Hannover and targeted an unspecified pathogen in poultry. The company develops novel veterinary vaccines using a proprietary technology platform based on the milk yeast Kluyveromyces lactis. These vaccines can be used to fight a number of different pathogens in various animal species and have low production costs.

The company has now successfully completed another major step in the development of veterinary vaccines. Verovaccines has secured additional funding from new investors from Germany and Switzerland for the validation of its proprietary technology platform as well as for the development of future veterinary vaccines. The objective is to scale up the production process to industrial level and to advance the development of products in the area of combination vaccines.

Dr Hanjo Hennemann, CEO of Verovaccines GmbH, is very pleased about the newly secured support: “Research and development in the biopharmaceutical industry place high demands on technology, products and resources. We are delighted that we have again attracted funding from private investors, in addition to acquiring public funding from the renowned GO‑Bio programme.”

About Verovaccines GmbH

Verovaccines GmbH is a spin-off founded by Professor Sven-Erik Behrens, Dr  Hanjo Hennemann and Dr Martina Behrens from Martin Luther University Halle-Wittenberg, Germany. The spin-off was established in July 2017.